<DOC>
	<DOCNO>NCT00716807</DOCNO>
	<brief_summary>Patients chronic masticatory muscle pain ( i.e. , pain great three month ) patient burn mouth syndrome participate study . The aim study compare pain kill effectiveness nalbuphine , narcotic pain killer , administer either placebo naloxone , drug use treat opiate overdose . A second goal determine sex difference two drug regimen . Drugs administer single-use intranasal spray device . All participant receive two spray ( one spray per nostril ) . One two spray nalbuphine ( 5 mg ) . The spray naloxone half participant placebo half .</brief_summary>
	<brief_title>Efficacy Nalbuphine Naloxone Administered Nose Sprays Treatment Orofacial Pain</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Burning Mouth Syndrome</mesh_term>
	<mesh_term>Facial Pain</mesh_term>
	<mesh_term>Temporomandibular Joint Disorders</mesh_term>
	<mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Clinical diagnosis temporomandibular muscle pain OR Clinical diagnosis burn mouth syndrome Pain duration : least 3 month Pain severity : 2 great 0 10 scale No adverse reaction study drug Not currently use narcotic analgesic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>BMS</keyword>
	<keyword>TMD</keyword>
</DOC>